Elrexfio Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of conventional chemotherapy, growth in lymphoma incidence, advances in monoclonal antibody science, improved cancer diagnostics, increasing oncology drug approvals.

The growth in the forecast period can be attributed to rising adoption of immunotherapies, expansion into additional indications, growth in precision oncology, increasing investment in biologics, improved patient survival outcomes. Major trends in the forecast period include bispecific antibody adoption, expansion of immuno oncology therapies, rising use in refractory lymphomas, preference for targeted cancer treatments, advancement in t cell engaging therapies.

The increasing prevalence of multiple myeloma is anticipated to drive the growth of the elrexfio market in the coming years. Multiple myeloma is a type of cancer that develops in plasma cells, a kind of white blood cell found in the bone marrow, leading to abnormal proliferation and accumulation of these cells, which can damage bones, kidneys, and other organs. The rising incidence of multiple myeloma is linked to factors such as an aging population, greater awareness, advancements in diagnostic methods, and improved access to healthcare, which enables better detection of the disease. Elrexfio (elranatamab) is a monoclonal antibody that treats multiple myeloma by binding to the BCMA (B-cell maturation antigen) protein on myeloma cells, thereby stimulating the immune system to destroy these cancerous cells. For example, in February 2023, Cancer Research UK projected that the annual number of new myeloma cases in the UK would rise from around 6,800 cases between 2023-2025 to approximately 8,300 between 2038 and 2040. Consequently, the growing prevalence of multiple myeloma is supporting the expansion of the elrexfio market.

The increase in healthcare expenditures is also expected to drive the growth of the elrexfio market. Healthcare spending encompasses all costs related to medical services, family planning, nutrition programs, and emergency health support. Expenditures have risen primarily due to the growing prevalence of chronic diseases, which increases demand for ongoing treatments, long-term medications, and frequent medical consultations. Higher healthcare spending facilitates the adoption of Elrexfio by allowing greater investment in advanced oncology therapies, enabling healthcare systems to allocate more resources to innovative bispecific treatments for multiple myeloma. For example, in May 2025, Statistics Netherlands reported that the Netherlands spent approximately $130.7 billion on healthcare in 2024, an increase of $9.79 billion or 8.1% compared to 2023. Thus, rising healthcare expenditures are contributing to the growth of the elrexfio market.

A key trend in the elrexfio market is the development of advanced therapies, such as B-cell maturation antigen-targeted treatments, to improve treatment outcomes for cancer and autoimmune diseases. BCMA-targeted therapy specifically focuses on the BCMA protein on malignant plasma cells, such as those in multiple myeloma. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, received FDA approval for elranatamab-bcmm (Elrexfio). This bispecific T-cell engager therapy targets BCMA on multiple myeloma cells and CD3 on T-cells, activating the immune system to combat relapsed or refractory multiple myeloma in adults who have undergone multiple prior treatments.

Major companies operating in the elrexfio market are Pfizer Inc.

North America was the largest region in the elrexfio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elrexfio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the elrexfio market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the elrexfio market by raising costs related to biologic drug manufacturing inputs, specialized vial systems, and temperature controlled logistics. Hospital based oncology treatment segments in north america and europe are most impacted due to reliance on imported biologics. These tariffs can contribute to higher therapy costs and slower adoption in cost sensitive regions. On the positive side, tariffs are driving pharmaceutical companies to localize biologics production and strengthen regional manufacturing ecosystems.

The elrexfio market research report is one of a series of new reports that provides elrexfio market statistics, including elrexfio industry global market size, regional shares, competitors with a elrexfio market share, detailed elrexfio market segments, market trends and opportunities, and any further data you may need to thrive in the elrexfio industry. This elrexfio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Elrexfio is the brand name for epcoritamab, a monoclonal antibody used to treat relapsed or refractory B-cell malignancies, especially B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab works by targeting and eliminating cancerous B-cells through engagement of CD3 on T-cells and CD20 on B-cells.

The primary indications for elrexfio include multiple myeloma and other hematologic cancers. Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow, leading to immune, bone, and organ damage, and can be treated with therapies like Elrexfio that target BCMA. The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, including hospitals, specialty clinics, research institutions, and others.

The elrexfio market consists of sales of combination therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.